undamentalytics Newsletter
Sign in

Traws Pharma, Inc. revenue

Traws Pharma, Inc.'s revenue was $2.8m in fiscal 2025, up 1134.5% on the year before. Since fiscal 2011 ($1.5m) it has grown at a compound 4.6% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue14651116112000003
Growth on the year before—+>999%−89.7%−83.2%+>999%−51.6%−85.8%+56.0%+77.8%−89.4%−2.2%0.0%0.0%0.0%+>999%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Traws Pharma, Inc. $2.8m 1134.5% 131.1%
Eyepoint, Inc. $2.8m -94.6% -57.9%
Therapeuticsmd, Inc. $3.3m 27.8% -63.9%
China Pharma Holdings, Inc. $3.9m -11.0% -21.0%
Nutriband Inc. $1.6m -37.3% -10.8%
Lipocine Inc. $1.6m -62.7% 205.6%

Compare with peers

Head to head: EYPT vs TRAWTRAW vs TXMDCPHI vs TRAW

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Traws Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Traws Pharma, Inc.